Both Novo Nordisk (NYSE:NVO) and Sanofi (NYSE:SNY) said yesterday that they won FDA approval for pre-filled pens with drug combinations indicated for adults with Type II diabetes.
Paris-based Sanofi’s Soliqua 100/33 is an injectable medicine composed of 2 diabetes drugs – insulin glargine and lixisenatide. The drug is approved for adults with Type II diabetes not controlled with less than 60 units daily of long-acting basal insulin or lixisenatide. The pre-filled pen will be available in U.S. retail pharmacies in January, according to Sanofi.
Get the full story at our sister site, Drug Delivery Business News